Bevacizumab and weekly dose-dense paclitaxel and carboplatin in recurrent epithelial ovarian carcinoma: A phase II trial | ||
| SECI Oncology Journal | ||
| Volume 10, Issue 4, October 2022, Pages 259-265 | ||
| Abstract | ||
| Aim: The aim of this research was intended to assess the efficiency and safety of combining bevacizumab with weekly dose-dense carboplatin (C) and paclitaxel (T) in the treatment of platinum-resistant/sensitive recurrent epithelial ovarian cancer (EOC) that had been treated previously with three weekly cycles of paclitaxel/carboplatin (TC). Methods: We included 32 patients having recurrent EOC who were previously given 3 weekly TC. The subjects administered bevacizumab 10 mg/kg per two weeks in addition to weekly paclitaxel 80 mg/m2, following that carboplatin AUC 2 on the 1st, 8th, and 15th days of a 28-day cycle for six scheduled cycles. All participants in the study received bevacizumab on a maintenance basis (15 mg/kg every three weeks). The toxicity, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were the primary endpoints. Results: The ORR was at 62.5%. The median PFS was 14 months, and the 2-year PFS was 34.4%. The median OS was 20 months (95% confidence interval [CI] 16.9-23.1), and the 2-year OS was 37.8%. Adverse effects associated with treatment were tolerable, with just a single patient (3.1%) developing grade 4 neutropenia. The most often reported non-hematological side effect was grade 3 hypertension, which occurred in seven patients (21,9%). Conclusion: Bevacizumab in combination with dose-dense weekly TC is effective and tolerated properly in patients with recurring EOC previously treated with TC administered every three weeks. | ||
| Keywords | ||
| Bevacizumab; paclitaxel; carboplatin; recurrent epithelial ovarian carcinoma | ||
|
Supplementary Files
|
||
|
Statistics Article View: 43 |
||
